Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: At least 12-month follow-up

Chinese Medical Journal

Volumn 126, Issue 15, 2013, Pages 2826-2829

  Zhang, Cui Jian ^a   Zhao, Peng Ju ^b   Li, Xue Song ^a   Zhao, Jing ^c,d   Huang, Li Hua ^a   Song, Yi ^a   Gong, Kan ^a   Shen, Cheng ^a   Yu, Wei ^a   Song, Gang ^a   Zhao, Zheng ^a   Zhang, Zheng ^a   Zhang, Qian ^a   He, Zhi Song ^a   Jin, Jie ^a   Zhou, Li Qun ^e  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e PEKING UNIVERSITY   (China)

Author keywords

Efficacy; Metastatic; Renal cell carcinoma; Safety; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYELID EDEMA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; POTASSIUM BLOOD LEVEL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; SKIN EXFOLIATION; SKIN PIGMENTATION; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; YOUNG ADULT;

EID: 84880940177     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130265     Document Type: Article

References (16)

1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer. Cancer 2007; 109: 1763-1768.
2. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23: 202-212.
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-875.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
5. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141.
6. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon a-2a versus combination therapy with interferon a-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/ EORTC GU 30012): an open-label randomized trial. Lancet 2010; 375: 641-648.
7. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002; 11: 37-42.
8. Mendel DB, Laird AD, Xin XH, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
9. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
11. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamics relationship. Clin Cancer Res 2003; 9: 327-337.
12. Motzer RJ. Michaelson MD, Redman BG, Hudes GR, Wilding G, Giglin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
13. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-2524.
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
15. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and secondline treatment of metastatic renal cell cancer. Ann Oncol 2009; 20: 966-967.
16. Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, et al. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin Med J 2011; 124: 2920-2924.